Dry eye disease (DED) is a chronic, progressive disorder that begins subtly—often with intermittent ocular dryness or grittiness—but can escalate significantly if left unaddressed. Without timely intervention, inflammation-driven damage accumulates across the ocular surface, leading to corneal epitheliopathy, fluctuating vision, and functional impairment in daily activities and work performance. For patients diagnosed with early- to mid-stage dry eye, a critical clinical question arises: Which topical therapy can meaningfully alter disease trajectory—not just relieve symptoms, but halt or even reverse progression?
Among available pharmacologic options, low-concentration cyclosporine ophthalmic emulsion has emerged as a cornerstone of disease-modifying treatment. According to the *Clinical Practice Guidelines for Dry Eye: A Comprehensive Approach (2026)*, 0.05% cyclosporine ophthalmic emulsion is recommended as a first-line therapeutic agent for moderate dry eye. Similarly, the *Chinese Expert Consensus on Clinical Diagnosis and Management of Dry Eye (2024)* affirms that low-dose cyclosporine A eye drops demonstrate robust efficacy in controlling ocular surface inflammation, slowing structural deterioration, and preserving glandular function—with a favorable safety profile.
The pathophysiology of progressive dry eye centers on a self-perpetuating inflammatory cascade: chronic immune activation damages lacrimal glands, meibomian glands, and conjunctival goblet cells, ultimately compromising tear production and stability. Cyclosporine acts selectively on T-lymphocytes to suppress this inflammatory signaling at its source—interrupting the pathological loop before irreversible glandular atrophy or corneal compromise occurs.
Cyclosporine ophthalmic emulsion (Type II), marketed in China as Zirun®, is specifically indicated for patients with keratoconjunctivitis sicca associated with ocular surface inflammation and reduced aqueous tear production. When initiated early, it helps preserve lacrimal and meibomian gland integrity, mitigating long-term structural decline. Clinical evidence supports its role in enhancing basal tear secretion—not merely supplementing tears, but restoring endogenous function.
A key benefit observed in real-world practice is reduced dependence on artificial tears. As inflammation subsides and glandular activity improves, patients often require fewer preservative-containing lubricants—leading to measurable gains in comfort, visual consistency, and overall quality of life. This shift from symptomatic palliation to functional restoration underscores its value in early intervention strategies.
For clinicians managing patients with persistent dry eye symptoms lasting more than one month—including burning, foreign-body sensation, or blurred vision after screen use—prompt evaluation and consideration of anti-inflammatory therapy are essential. Delaying treatment risks progression to advanced disease, increasing susceptibility to sight-threatening complications such as corneal ulceration, persistent epithelial defects, and permanent visual decline.
Practical Recommendations:
• Seek ophthalmologic assessment for symptoms persisting beyond four weeks.
• Avoid prolonged, unsupervised use of preserved artificial tears, which may exacerbate epithelial toxicity.
• Address modifiable risk factors: digital screen overuse, insufficient blink rate, sleep deprivation, and environmental desiccation.
• Undergo annual ocular surface evaluation—including tear film break-up time, Schirmer testing, and meibomian gland imaging—as part of routine eye health maintenance.
Frequently Asked Questions:
Q: Is cyclosporine appropriate for mild dry eye?
A: In cases where symptoms are infrequent and fully controlled with occasional artificial tears, conservative management—such as lid hygiene, environmental modification, and dietary omega-3 supplementation—may suffice. However, if symptoms become persistent or artificial tears lose effectiveness, early anti-inflammatory therapy is warranted to prevent transition to moderate disease.
Q: Can patients become dependent on cyclosporine eye drops?
A: No. Cyclosporine does not induce pharmacologic dependence or tolerance. Its mechanism targets underlying inflammation and glandular dysfunction; once disease activity stabilizes, gradual tapering under clinical supervision is both safe and feasible.
In summary, cyclosporine ophthalmic emulsion (Type II) represents a validated, evidence-based strategy for modifying the natural history of dry eye disease. Its integration into early-stage management aligns with contemporary paradigms emphasizing disease stabilization over symptom masking—offering patients not only symptomatic relief but also meaningful protection against long-term ocular surface morbidity.